About – Baltimore Biotechnologies

WHO WE ARE AND WHAT WE DO

Baltimore Biotechnologies is an established oncology research company focused on genomic research. Our focus is on providing data-driven intelligence as a transformational tool in medical oncology.

The company was founded in 2019 by a highly experienced management team with a rich knowledge and understanding of the global genomics market and healthcare. Baltimore Biotechnologies is based in Dublin Ireland.

Our vision is to be at the forefront of Irish genomic health research and cancer detection and treatment. We intend to participate in the transformation of global healthcare through close partnerships and to democratise genomic healthcare by empowering citizen choice and transparency whilst at the same time providing total security of participants data.

OUR TEAM

David Rafferty

David is a seasoned Healthcare Business Consultant & entrepreneur with over 30 years of national and international senior leadership roles in healthcare and other business sectors. David worked for several blue-chip pharma companies with leadership positions in Europe and the US. He has played an active role in several start-ups and has advised SME’s and international blue chip organizations. He was recently VP of Business Development for Genomics Medicine Ireland. He is a graduate of Trinity College Dublin and has a BA (Mod) in molecular genetics and an MBA.

Oliver Tattan

Oliver is a founder of two health insurers, now merged to form Irish Life Health. He also co-founded Regulatory Capital a provider of capital to insurers; Daon, a biometric identity provider; OneBigSwitch, a consumer switching platform and Genebox, a genomics company. He is Chairman of Fadata, a European leader in insurance PaaS, and Brookson, a platform for independent contractors, both owned by Riverside, a US private equity company. Oliver is an INED with BMW Financial Services and previously served as INED with AGF International, a Canadian asset manager. He chaired several Government funded research centres and taskforces. He also served as INED and Chairman of the Remuneration Committee of CPL Resources plc, a listed human resources company and chaired the Finance Committee at space researcher SETI in California. Earlier, Oliver served as CEO of VHI, an insurance company, and as CEO of An Bord Trachtala, a state agency for SMEs. He co-founded a political party to campaign for a ‘yes’ vote in the Lisbon Treaty referendum. He holds an MBA from INSEAD in France, a B.E. (Chem) from University College Dublin and speaks German and Portuguese.

Peter O’Brien

As co-founder of Artelo Biosciences, NASDAQ, Peter up listed Artelo Biosciences onto the NASDAQ in June 2019, from start up in under 3 years. Peter has an accomplished record of creating, leading and selling multiple businesses including Medical Staff Ireland, Nursing Station and Driver and Labour Recruit. Mr. O’Brien also co-founded SPR Global Technologies (medical technology) which was acquired in 2018. Previously, he was a specialist in the private client sector at HSBC International in Jersey, Channel Island, and UK.

Sean Ennis - Scientific Advisor

Sean is a lecturer at the School of Medicine & Medical Sciences at UCD, Investigator with the National Centre for Medical Genetics and National Children’s Research Centre. He is director of the UCD Academic Centre of Rare Diseases (ACoRD). He has life-long experience in research in medical genetics. He has led and been involved in establishing collaborative approaches to investigating chronic conditions such as Motor Neuron Disease (ALS), Autism Spectrum Disorder and, more recently, Rare Diseases. He has extensive published research studies and is a frequent speaker in the area of genomics.